China’s Bio-Thera Solutions licenses its arthritis drug to Germany’s STADA
HONG KONG (Reuters) -China’s Bio-Thera Solutions said on Thursday it has granted Germany’s STADA Arzneimittel commercialisation rights for its arthritis drug BAT1806 in the EU, UK, Switzerland, certain Middle East and North Africa regions, and certain members of the Commonwealth of Independent States. Upfront payment and milestone payments will total up to 136 million euros …
China’s Bio-Thera Solutions licenses its arthritis drug to Germany’s STADA Read More »









